BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 22706571)

  • 21. Effects of intravenous polymaltose iron on oxidant stress and non-transferrin-bound iron in hemodialysis patients.
    Driss F; Vrtovsnik F; Katsahian S; Michel C; Baron G; Kolta A; Sedrati N; Mentré F; Mignon F; Cabantchik I; Grandchamp B
    Nephron Clin Pract; 2005; 99(3):c63-7. PubMed ID: 15640610
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A pilot evaluation of the long-term effect of combined therapy with intravenous iron sucrose and erythropoietin in elderly patients with advanced chronic heart failure and cardio-renal anemia syndrome: influence on neurohormonal activation and clinical outcomes.
    Comín-Colet J; Ruiz S; Cladellas M; Rizzo M; Torres A; Bruguera J
    J Card Fail; 2009 Nov; 15(9):727-35. PubMed ID: 19879457
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A vitamin E-coated polysulfone membrane reduces serum levels of inflammatory markers and resistance to erythropoietin-stimulating agents in hemodialysis patients: results of a randomized cross-over multicenter trial.
    Panichi V; Rosati A; Paoletti S; Ferrandello P; Migliori M; Beati S; Bernabini G; Daini R; Casani A; Angelini D; Parrini M; Rossi A; Petrone I; Barsotti G; Donadio C; Donati G; Grazi G; Manca Rizza G; Garosi G; Sansoni E; Braccagni B; Sidoti A; Boracelli D; Biagioli M; Moriconi L; Finato V; Mannarino A; Grimaldi C; Pansa F; Imperiali P; Mura C; Bianchi S; Bigazzi R
    Blood Purif; 2011; 32(1):7-14. PubMed ID: 21242686
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Administration of exogenous erythropoietin beta affects lipid peroxidation and serum paraoxonase-1 activity and concentration in predialysis patients with chronic renal disease and anaemia.
    Marsillach J; Martínez-Vea A; Marcas L; Mackness B; Mackness M; Ferré N; Joven J; Camps J
    Clin Exp Pharmacol Physiol; 2007 Apr; 34(4):347-9. PubMed ID: 17324148
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of intravenous iron supplementation on hepatic cytochrome P450 3A4 activity in hemodialysis patients: a prospective, open-label study.
    Pai AB; Norenberg J; Boyd A; Raj D; Chan LN
    Clin Ther; 2007 Dec; 29(12):2699-705. PubMed ID: 18201586
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lipid peroxidation products formation with various intravenous iron preparations in chronic kidney disease.
    Ganguli A; Kohli HS; Khullar M; Lal Gupta K; Jha V; Sakhuja V
    Ren Fail; 2009; 31(2):106-10. PubMed ID: 19212906
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of ascorbate-rich dialysate to attenuate oxidative stress in maintenance hemodialysis patients.
    Shi XF; Ding F; Zhu QY; Xue J; Lu FM; Gu Y; Lin ST
    Ren Fail; 2005; 27(2):213-9. PubMed ID: 15807188
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease.
    Agarwal R; Vasavada N; Sachs NG; Chase S
    Kidney Int; 2004 Jun; 65(6):2279-89. PubMed ID: 15149341
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lipoperoxidation and hemodialysis.
    Ramos R; Martínez-Castelao A
    Metabolism; 2008 Oct; 57(10):1369-74. PubMed ID: 18803940
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of iron treatment on circulating cytokine levels in ESRD patients receiving recombinant human erythropoietin.
    Weiss G; Meusburger E; Radacher G; Garimorth K; Neyer U; Mayer G
    Kidney Int; 2003 Aug; 64(2):572-8. PubMed ID: 12846752
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Haemodialysis induces mitochondrial dysfunction and apoptosis.
    Raj DS; Boivin MA; Dominic EA; Boyd A; Roy PK; Rihani T; Tzamaloukas AH; Shah VO; Moseley P
    Eur J Clin Invest; 2007 Dec; 37(12):971-7. PubMed ID: 18036031
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of plasma F2-isoprostanes and isofurans concentrations with erythropoiesis-stimulating agent resistance in maintenance hemodialysis patients.
    Rivara MB; Ikizler TA; Ellis CD; Mehrotra R; Himmelfarb J
    BMC Nephrol; 2015 Jun; 16():79. PubMed ID: 26045064
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Protective effect of vitamin C on 8-hydroxy-2'-deoxyguanosine level in peripheral blood lymphocytes of chronic hemodialysis patients.
    Tarng DC; Liu TY; Huang TP
    Kidney Int; 2004 Aug; 66(2):820-31. PubMed ID: 15253739
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High-dose intravenous vitamin C is not associated with an increase of pro-oxidative biomarkers.
    Mühlhöfer A; Mrosek S; Schlegel B; Trommer W; Rozario F; Böhles H; Schremmer D; Zoller WG; Biesalski HK
    Eur J Clin Nutr; 2004 Aug; 58(8):1151-8. PubMed ID: 15054428
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oral ferrous fumarate or intravenous iron sucrose for patients with inflammatory bowel disease.
    Erichsen K; Ulvik RJ; Nysaeter G; Johansen J; Ostborg J; Berstad A; Berge RK; Hausken T
    Scand J Gastroenterol; 2005 Sep; 40(9):1058-65. PubMed ID: 16165718
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency.
    Toblli JE; Lombraña A; Duarte P; Di Gennaro F
    J Am Coll Cardiol; 2007 Oct; 50(17):1657-65. PubMed ID: 17950147
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intravenous ascorbic acid in hemodialysis patients with functional iron deficiency: a clinical trial.
    Giancaspro V; Nuzziello M; Pallotta G; Sacchetti A; Petrarulo F
    J Nephrol; 2000; 13(6):444-9. PubMed ID: 11132761
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oxidative stress and erythrocyte integrity in end-stage renal failure patients hemodialysed using a vitamin E-modified membrane.
    Westhuyzen J; Saltissi D; Stanbury V
    Ann Clin Lab Sci; 2003; 33(1):3-10. PubMed ID: 12661892
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antioxidant supplementation decreases lipid peroxidation biomarker F(2)-isoprostanes in plasma of smokers.
    Dietrich M; Block G; Hudes M; Morrow JD; Norkus EP; Traber MG; Cross CE; Packer L
    Cancer Epidemiol Biomarkers Prev; 2002 Jan; 11(1):7-13. PubMed ID: 11815395
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differences between original intravenous iron sucrose and iron sucrose similar preparations.
    Toblli JE; Cao G; Oliveri L; Angerosa M
    Arzneimittelforschung; 2009; 59(4):176-90. PubMed ID: 19517894
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.